Major shareholder rejects Lonza bid for Patheon
Lonza (Switzerland) has submitted a non-binding proposal that would see it acquire all of the Restricted Voting Shares of US-based Patheon Inc.
Lonza (Switzerland) has submitted a non-binding proposal that would see it acquire all of the Restricted Voting Shares of US-based Patheon Inc. However, a 
"JLL is not interested in selling its position in Patheon at this time. JLL will not enter into negotiations regarding the Lonza proposal and Patheon shareholders should be aware that a transaction with Lonza cannot occur without JLL's support," said the JLL statement.
JLL made 
"Based on all the information available to it, the Special Committee's view has been that Patheon continuing as an independent company is a more attractive alternative to the JLL offer," Paul Currie, Chairman of the Special Committee of Independent Directors of Patheon, explained in a 
Lonza also seems enthusiastic. "Our interest in Patheon is consistent with Lonza's strategy of expanding our offering across the pharmaceutical manufacturing value chain," Lonza's CEO, Stefan Borgas, said in the joint statement.
But whether the transaction will take place remains to be seen. Lonza has signed a confidentiality and standstill agreement, and Patheon has agreed not to negotiate an acquisition transaction with any other party until 30 September 2009. However, JLL is adamant that it "holds Restricted Voting Shares that represent approximately 57% of the shares outstanding" and that "the Lonza proposal is conditioned on, among other things, acceptance of the Lonza proposal by the holders of at least 67% of the outstanding Patheon Restricted Voting Shares".
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

